National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cenobamate (Ontozry®). HTA ID: 21025

Cenobamate is indicated for the adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/06/2021
Rapid review completed 05/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cenobamate compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/07/2021
Pre-submission consultation with Applicant 06/09/2021
Full HTA submission received from Applicant 13/12/2021
Preliminary review sent to Applicant 27/04/2022
NCPE assessment re-commenced 27/05/2022
Factual accuracy check sent to Applicant 04/08/2022
NCPE assessment re-commenced 11/08/2022
NCPE assessment completed 06/10/2022
NCPE assessment outcome The NCPE recommends that cenobamate (Ontozry®) be considered for reimbursement as a second- or subsequent-line adjunctive treatment of focal onset seizures in adult patients with epilepsy who have failed treatment with two or more previous anti-seizure medicines, including at least one adjunctive therapy*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.